1. Scrip
  2. >>New Products

Syndax Scores First-Mover Advantage With Approval Of Menin Inhibitor For Leukemia

 
• By Alaric DeArment

The drug maker anticipates a potential label expansion for Revuforj (revumenib) from KMTA2-translocation acute leukemias into NPM1-mutant AML.

Gold "FDA approved" label
(Shutterstock)

Syndax Pharmaceuticals will have a first-mover advantage as it launches Revuforj (revumenib) for relapsed/refractory acute leukemias in adult and pediatric patients with KMT2A translocations, following the drug’s US Food and Drug Administration approval.

The FDA approved Revuforj on 15 November as the first menin inhibitor, for patients aged 1 and older with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or mixed phenotype...

Key Takeaways
  • The FDA approved Syndax’s Revuforj as the first menin inhibitor, for acute leukemias with KMT2A translocations and a potential label expansion into NPM1-mutant AML on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

More from Therapy Areas

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.